Use of REGEN-COV in children after heart transplantation for treatment and post-exposure prophylaxis of COVID-19

Dipankar Gupta; Stephanie A Clifford; Frederick J Fricker

doi:10.1017/S1047951122002190

Use of REGEN-COV in children after heart transplantation for treatment and post-exposure prophylaxis of COVID-19

Cardiol Young. 2023 Mar;33(3):496-497. doi: 10.1017/S1047951122002190. Epub 2022 Jul 7.

Authors

Dipankar Gupta^{1

2}, Stephanie A Clifford^{1

3}, Frederick J Fricker^{1

2}

Affiliations

¹ Congenital Heart Center, Shands Children's Hospital, University of Florida, Gainesville, FL, USA.
² Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL, USA.
³ College of Nursing, University of Florida, Gainesville, FL, USA.

Abstract

COVID-19 pandemic continues to evolve and new variants like Delta and Omicron have been discovered. REGEN-COV is a recombinant human monoclonal antibody to the spike protein of SARS-CoV-2 which received emergency use authorisation for treatment and post-exposure prophylaxis in patients with high risk of progression to severe disease. We review our experience with use of REGEN-COV in paediatric heart transplant patients.

Keywords: COVID-19; REGEN-COV; paediatric heart transplant.

MeSH terms

COVID-19*
Child
Heart Transplantation*
Humans
Pandemics / prevention & control
Post-Exposure Prophylaxis
SARS-CoV-2

Substances

casirivimab and imdevimab drug combination